Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Bendamustine in Relapsed/Refractory Hodgkin's Lymphoma
NCT01535924Phase 2Completed
- Start
- Feb 2012
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine in Hodgkin lymphoma (HL). Primary endpoints: Dose-limiting Toxicity up to 5 years and Maximum Tolerated Dose up to 5 years. Started Feb 2012; status: completed.
02
Drugs
bendamustine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01535924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01535924.